Prophylaxis followed by Preemptive Approach versus Prophylaxis to Prevent CMV Infection in CMV-Seropositive Kidney Transplant Recipients Receiving Anti-thymocyte Globulin Induction Therapy
Phase 3
Recruiting
- Conditions
- How to prevent CMV infection in seropositive KT recipients receiving ATG induction therapyCMV, preemptive approach, valganciclovir
- Registration Number
- TCTR20240622001
- Lead Sponsor
- Faculty of Medicine Ramathibodi Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Kidney transplant at age 15 years or older
Receiving ATG as induction therapy
CMV-seropositive status
Exclusion Criteria
denied to participate
allergic to valganciclovir or ganciclovir
Those with CMV infection at the time of inclusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CMV Infection 6 months check plasma CMV viral load
- Secondary Outcome Measures
Name Time Method Allograft rejection 6 months creatinine